Crohn Disease
📧 Sign up to get email alerts when something new happens for Crohn Disease.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2024-03-14FDA Approved: ENTYVIO — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for ENTYVIO (vedolizumab) from Takeda Pharmaceuticals America, Inc., approving a modification to the…
-
CLINICAL_TRIALS trial_result · 2024-03-12Clinical Trial Update: Fluorescence Imaging of Adalimumab-680LT in Inflammatory Bowel Disease [Phase 1, Phase 2]
Clinical trial update on fluorescence imaging of adalimumab-680LT in inflammatory bowel disease (Crohn's disease and ulcerative colitis) acr…
-
CLINICAL_TRIALS trial_result · 2024-03-05Clinical Trial Update: Top-down Infliximab Study in Kids With Crohn's Disease [Phase 4]
Phase 4 clinical trial update for top-down infliximab in pediatric Crohn's disease has completed.
-
FDA approval · 2024-03-01FDA Approved: MESALAMINE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for Mesalamine from Mylan Pharmaceuticals Inc. The action grants a supplemental approval for this ge…
-
CLINICAL_TRIALS trial_result · 2024-02-26Clinical Trial Update: Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis [Phase 1]
Phase 1 trial evaluating MDGN-002 in adults with Crohn's disease or ulcerative colitis has been terminated.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2024-02-23FDA Approved: ENTYVIO — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for ENTYVIO (vedolizumab) submitted by Takeda Pharmaceuticals America, Inc.
-
FDA approval · 2024-02-23FDA Approved: ENTYVIO — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for ENTYVIO (vedolizumab) submitted by Takeda Pharmaceuticals America, Inc.
-
FDA approval · 2024-02-22FDA Approved: ZYMFENTRA — Supplemental Application (CELLTRION USA Inc.)
The FDA approved a supplemental application for ZYMFENTRA (infliximab-dyyb) submitted by Celltrion USA Inc.
-
CLINICAL_TRIALS trial_result · 2024-02-16Clinical Trial Update: A Study Testing How BI 655130 Works in Patients With Fistulizing Crohn's Disease [Phase 2]
This Phase 2 trial of BI 655130 for fistulizing Crohn's disease has completed, with results posted on February 16, 2024.
-
CLINICAL_TRIALS trial_result · 2024-01-30Clinical Trial Update: Extracorporeal Photopheresis of Patients With Crohn's Disease Using 5-aminolevulinic Acid [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating extracorporeal photopheresis with 5-aminolevulinic acid for Crohn's disease has completed recruitment.
-
FDA approval · 2023-12-26FDA Approved: RENFLEXIS — Supplemental Application (Organon LLC)
FDA approved a supplemental application for Renflexis (infliximab) submitted by Organon LLC.
-
CLINICAL_TRIALS trial_result · 2023-12-18Clinical Trial Update: Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease [Phase 3]
Phase 3 trial evaluating filgotinib for induction and maintenance of remission in adults with moderately to severely active Crohn's disease …
-
FDA approval · 2023-12-15FDA Approved: HULIO — Supplemental Application (Biocon Biologics Inc)
The FDA approved a supplemental application for HULIO, Biocon Biologics' biosimilar adalimumab (adalimumab-fkJP).
-
CLINICAL_TRIALS trial_result · 2023-12-07Clinical Trial Update: Transversus Abdominis Plane Blocks With and Without Dexamethasone [Phase 1, Phase 2]
A clinical trial update on transversus abdominis plane blocks with and without dexamethasone across Phase 1 and Phase 2 stages, with unclear…
-
CLINICAL_TRIALS trial_result · 2023-12-06Clinical Trial Update: Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease [Phase 2]
A Phase 2 study evaluating the testicular safety of filgotinib in adult males with inflammatory bowel disease was terminated; results have b…
-
FDA approval · 2023-12-05FDA Approved: PREDNISONE TABLETS, USP, 5 MG — Supplemental Application (Granulation Technology, Inc.)
FDA granted a supplemental approval for Prednisone Tablets, USP, 5 mg to authorize a granulation technology manufacturing change by Granulat…
-
CLINICAL_TRIALS trial_result · 2023-12-04Clinical Trial Update: Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease [Phase 2]
Phase 2 trial of oral BT-11 in moderate to severe Crohn's disease was terminated; results posted in 2023.
-
FDA approval · 2023-11-30FDA Approved: ADALIMUMAB — Supplemental Application (CELLTRION USA, Inc.)
The FDA approved a supplemental Biologics License Application for the adalimumab biosimilar ADALIMUMAB-AATY from Celltrion USA, Inc., allowi…
-
FDA approval · 2023-11-27FDA Approved: MESALAMINE — Supplemental Application (Zydus Lifesciences Limited)
The FDA approved a supplemental application for mesalamine from Zydus Lifesciences Limited, authorizing changes described in the submission.
-
CLINICAL_TRIALS trial_result · 2023-11-27Clinical Trial Update: Therapeutic Optimization Study Based on MR Enterocolonography in Patients With Crohn's Disease [Phase 3]
Phase 3 clinical trial update on therapeutic optimization using MR enterocolonography in Crohn's disease.
-
CLINICAL_TRIALS trial_result · 2023-11-21Clinical Trial Update: An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease [Phase 2, Phase 3]
A clinical trial update indicates Brazikumab in moderately to severely active Crohn's disease (IBD) was terminated in a combined Phase 2/Pha…
-
CLINICAL_TRIALS trial_result · 2023-11-18Clinical Trial Update: Extension Study of Semapimod 60 mg IV x 3 Days [Phase 2]
Phase 2 extension study update for semapimod IV in Crohn's disease; study completed.
-
CLINICAL_TRIALS trial_result · 2023-11-18Clinical Trial Update: Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Disease [Phase 4]
Phase 4 extended access trial of vedolizumab IV in ulcerative colitis and Crohn's disease has been terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2023-11-13Clinical Trial Update: A Safety and Efficacy Study of BLI-1300 Ointment in Symptomatic Perianal Crohn's Disease [Phase 2]
Phase 2 trial of BLI-1300 ointment for symptomatic perianal Crohn's disease was terminated; results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-11-09Clinical Trial Update: Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus Placebo [Phase 2]
Phase 2 trial evaluating semapimod for moderate to severe Crohn's disease compared to placebo has been completed.